Peptide ligand to impair cancer cell migration

US8674060B2 · kind B2 · utility

Assignee

• WNTRESEARCH AB · SE

Inventor

• Tommy Andersson · Sundbyberg, SE

Key dates

• Filing date: Nov 28, 2007
• Grant date: Mar 18, 2014
• Expiry date: Jan 25, 2030

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Loss of Wnt-5a protein expression in breast carcinoma patients is associated with a shorter recurrence-free survival as well as increased motility in mammary cell lines. Based on sequence analysis of Wnt-5a, peptide fragments were identified and investigated for their ability to mimic effects of the Wnt-5a protein on mammary cell adhesion and motility. Two of these peptides significantly increased adhesion and impaired the motility of non-tumorigenic breast cancer cell lines, both low in endogenous Wnt-5a protein expression. To identify the shortest possible peptide that still had an anti-motile effect, sequential deletions of two amino acids from the N-terminal side of the shorter of these two peptides were performed. The effect on tumor cell adhesion was gradually lost, and when only 6 amino acids remained the effect was not detectable. However, formulation of the N-terminal methionine of this hexapeptide restored its effect on adhesion and reduced tumor cell motility. The formyl-Met-Asp-Gly-Cys-Glu-Leu (formylated SEQ ID NO: 15) peptide ligand can serve as a lead substance for anti-metastatic treatment in the 50% of human breast cancers where the endogenous expression of Wnt-5a …